Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance)
- Citation:
- J Clin Oncol vol 34 (4s) abstr 192
- Meeting Instance:
- ASCO GI 2016
- Year:
- 2016
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Corresponding Author: Ghassan Abou-Alfa
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3009
- Pharmas:
- Bayer Healthcare; Berlex
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Ghassan K. Abou-Alfa Donna Niedzwiecki Jennifer J. Knox Andreas Kaubisch James Posey Benjam R. Tan Jr. Peter Kavan Rakesh Goel John J. Murray Tanios S. Bekaii-Saab Vincent Channing Tam Lakshmi Rajde Robin Kate Kelley Abby Siegel Jennifer Balletti James J. Harding Lawrence Howard Schartz Richard M. Goldberg Monica M. Bertagnolli Alan P. Venook
- Networks:
- CA136, COLUMBIA, LAPS-MA036, LAPS-MN026, LAPS-NY016, LAPS-OH007, MN022, MONTEFIORE, PA121, TN118
- Study
- CALGB-80802
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Sorafenib